Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03040778 · ClinicalTrials.gov registry record · Phase 3

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

A Phase 3 study, sponsored by University of Washington.

Active
Registry status
Phase 3
Development phase
100
Enrollment target

NCT03040778: Active Phase 3 study, sponsored by University of Washington.

NCT03040778 is a Phase 3 study that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03040778, a Phase 3 study, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
100 participants
Enrollment target

Study Summary

The overall purpose of this project is to answer the following clinical question: Among Medication-Related Osteonecrosis of the Jaw (MRONJ) patients, do those who are treated with the Pentoxifylline and Tocopherol (PENTO) regimen and standard of care, when compared to those treated with standard of care alone, have decreased areas of exposed bone after one year of treatment?

Primary Outcome

The primary lesion's area of exposed bone will be estimated by measuring the greatest anterior-posterior and superior-inferior dimensions in millimeters (mm) of the site with the largest area of exposed bone present at the time of study enrollment. If there are multiple areas of exposed bone in a single patient, the site with the largest sum of linear anterior-posterior and superior-inferior dimensions will be included in the study.

Interventions

  • DRUG Placebo
  • DRUG Pentoxifylline
  • DRUG Tocopherol

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2018-04-01
Est. Completion 2026-06-30
Phase Phase 3
University of Washington

1,048 total trials

What the registry record for NCT03040778 still lists

NCT03040778 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03040778 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03040778 about?

NCT03040778 is a clinical study titled "Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)". The overall purpose of this project is to answer the following clinical question: Among Medication-Related Osteonecrosis of the Jaw (MRONJ) patients, do those who are treated with the Pentoxifylline and Tocopherol (PENTO) regimen and standard of care, when compared to those treated with standard of ...

What is the current status of trial NCT03040778?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2018-04-01. Estimated completion is 2026-06-30.

What interventions are being tested in trial NCT03040778?

The interventions under investigation include: Placebo (DRUG), Pentoxifylline (DRUG), Tocopherol (DRUG).

Who is sponsoring clinical trial NCT03040778?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03040778's enrollment target sits among peer trials

100 1681st of 2000 higher than 288 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03040778, the US trial registry maintained by the National Library of Medicine. NCT03040778 (mid enrollment · none site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.